US006486168B1

(12) **United States Patent**
Skwierczynski et al.

(10) **Patent No.: US 6,486,168 B1**
(45) **Date of Patent: Nov. 26, 2002**

(54) **FORMULATIONS AND METHODS FOR TREATMENT OF MUCOSAL ASSOCIATED CONDITIONS WITH AN IMMUNE RESPONSE MODIFIER**

(75) Inventors: **Raymond D. Skwierczynski**, Oakdale, MN (US); **Kenneth R. Phares**, Chapel Hill, NC (US); **Richard L. Miller**, Maplewood, MN (US); **Zheng Jane Li**, Quaker Hill, CT (US); **Michael J. Jozwiakowski**, Stillwater, MN (US); **Terri F. Busch**, St. Paul, MN (US)

(73) Assignee: **3M Innovative Properties Company**, St. Paul, MN (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **09/676,339**

(22) Filed: **Sep. 29, 2000**

Related U.S. Application Data

(63) Continuation of application No. 09/479,578, filed on Jan. 7, 2000, now Pat. No. 6,245,776.
(60) Provisional application No. 60/115,256, filed on Jan. 8, 1999.

(51) **Int. Cl.**[7] **A61K 31/44**
(52) **U.S. Cl.** **514/293**
(58) **Field of Search** 514/293

(56) **References Cited**

U.S. PATENT DOCUMENTS

3,314,941 A	4/1967	Littell et al.	
3,917,624 A	11/1975	El-Haj et al.	
4,689,338 A	8/1987	Gerster	
4,698,348 A	10/1987	Gerster	
4,929,624 A	5/1990	Gerster et al.	
4,988,815 A	1/1991	Andre et al.	
5,037,986 A	8/1991	Gerster	
5,175,296 A	12/1992	Gerster	
5,238,944 A	8/1993	Wick et al.	
5,266,575 A	11/1993	Gerster et al.	
5,268,376 A	12/1993	Gerster	
5,346,905 A	9/1994	Gerster	
5,352,784 A	10/1994	Nikolaides et al.	
5,367,076 A	11/1994	Gerster	
5,389,640 A	2/1995	Gerster et al.	
5,395,937 A	3/1995	Nikolaides et al.	
5,444,065 A	8/1995	Nikolaides et al.	
5,446,153 A	8/1995	Lindstrom et al.	
5,482,936 A	1/1996	Lindstrom	
5,494,916 A	2/1996	Lindstrom et al.	
5,525,612 A	6/1996	Gerster	
5,585,612 A	12/1996	Harp, Jr.	
5,605,899 A	2/1997	Gerster et al.	
5,627,281 A	5/1997	Nikolaides et al.	
5,644,063 A	7/1997	Lindstrom et al.	
5,648,516 A	7/1997	Nikolaides et al.	
5,714,608 A	2/1998	Gerster	
5,741,908 A	4/1998	Gerster et al.	
5,741,909 A	4/1998	Gerster et al.	
5,886,006 A	3/1999	Nikolaides et al.	
5,977,366 A	11/1999	Gerster et al.	
6,069,149 A	5/2000	Nanba et al.	
6,245,776 B1 *	6/2001	Skwierczynski et al.	514/293

FOREIGN PATENT DOCUMENTS

EP	0 894 797 A1	2/1998
JP	9-208584	8/1997
WO	93/09119	5/1993
WO	97/418884	11/1997
WO	97/48704	12/1997
WO	98/24436	6/1998
WO	99/29693	6/1999
WO	00/06577	2/2000
WO	00/09506	2/2000
WO	00/40228	7/2000

OTHER PUBLICATIONS

Wozniak, et al, "The Amination of 3–nitro–1, 5–naphthyridines by Liquid Ammonia/Potassium Permanganate[1,2]. A New and Convenient Amination Method.", Journal of the Royal Netherlands Chemical Society, 102, pp. 511–513, Dec. 12, 1983.

Brennan, et al, "Automated Bioassay of Interferons in Micro–test Plates", *Biotechniques,* Jun./Jul., 78, 1983.

Testerman, et al, "Cytokine Induction by the Immunomodulators Imiquimod and S–27609", Journal of Leukocyte Biology, vol. 58, pp. 365–372, Sep. 1995.

Bachman, et al, "Synthesis of Substituted Quinolylamines. Derivatives of 4–Amino–7–Chloroquinoline", J. Org. Chem, 15, pp. 1278–1284 (1950).

Jain, et al, "Chemical and Pharmacological Investigations of Some ω–Substituted Alkylamino–3–aminopyridines", J. Med. Chem., 11, pp. 87–92 (1968).

Baranov, et al., Chem. Abs. 85, 94371, (1976).

Berényi, et al, "Ring Transformation of Condensed Dihydro–as–triazines", *J. Heterocyclic Chem.,* 18, pp. 1537–1540 (1981).

R. Snoeck, G. Andrei and E. De Clercq, "Specific Therapies for Human Papilloma Virus Infections", Current Opionion in Infectious Diseases, 1998, vol. 11, pp. 733–737.

"3M Pharmaceuticals unveils research and development and expansion plans" retrieved from STN International, No. 2138, p. 10–. . . (1996).

(List continued on next page.)

Primary Examiner—Raymond Henley, III
(74) *Attorney, Agent, or Firm*—MarySusan Howard; Ted K. Ringsred

(57) **ABSTRACT**

Immune response modifier (IRM) compounds—imidazoquinoline amines, imidazopyridine amines, 6,7-fused cycloalkylimidazopyridine amines, 1,2-bridged imidazoquinoline amines, thiazolo- and oxazoloquinolinamines and pyridinamines, imidazonaphthyridine and tetrahydroimidazonaphthyridine amines—are useful for the treatment of conditions at and below the mucosal surfaces by administering a therapeutically effective amount of such compounds to the mucosal surface. Novel pharmaceutical formulations are provided. In one embodiment, the pharmaceutical formulations are advantageous for treatment of cervical conditions such as cervical dysplasias including cervical intraepithelial neoplasias.

16 Claims, 3 Drawing Sheets